Opinion|Videos|February 5, 2025
Genetic Testing and Molecular Profiling in AML
Panelists discuss the importance of genetic testing, particularly for KMT2A and NPM1 mutations, in identifying patients who would benefit from revumenib, the role of molecular profiling in identifying high-risk acute monocytic leukemia (AML) patients, approaches to KMT2A testing, and when to recommend RNA over DNA testing, along with guidance for institutions lacking standardized diagnostic testing protocols.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Dr. LeBlanc to ask Dr. Goldberg: Highlight the importance of genetic testing, specifically KMT2A and NPM1, in identifying patients who would benefit from revumenib.
- Dr. LeBlanc to ask Dr. Blachly: Briefly comment on the role of molecular profiling in identifying high-risk patients with AML.
- Dr. LeBlanc to ask Dr. 4: How do you approach KMT2A testing and when would you recommend RNA over DNA testing? And why?
- What guidance would you offer to institutions that do not yet have standardized diagnostic testing protocols?
- Dr. LeBlanc to ask Dr. 4: How do you approach KMT2A testing and when would you recommend RNA over DNA testing? And why?
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover pancreatic cancer, gastric cancer, GIST, renal cell carcinoma, and chronic lymphocytic leukemia.
DESTINY-Breast05 Safety Analysis Clarifies ILD and Radiation Risks With T-DXd in HER2+ Breast Cancer
Charles E. Geyer, MD, discusses data from the DESTINY-Breast05 safety analysis evaluating ILD and radiation pneumonitis outcomes in HER2+ breast cancer.
The FDA approved daraxonrasib for pancreatic cancer, cleared zanidatamab-based regimens for HER2-positive gastric cancer, and more.
The selective ROCK2 inhibitor TDI01 generated organ-wide responses in previously treated moderate-to-severe chronic graft-versus-host disease, with the 400-mg dose performing best.
The FDA approved rusfertide for the treatment of patients with polycythemia vera.
Patient-reported QOL and symptom outcomes were similar between belzutifan plus lenvatinib and cabozantinib in previously treated RCC.
The phase 3 DAWN-303 trial is evaluating the oral KRAS G12D inhibitor INCB161734 in previously untreated, KRAS G12D–mutated metastatic PDAC.
Richard K. and Nancy K. Lubin have made a $35 million gift to Dana-Farber Cancer Institute’s Future of Cancer Care Fund.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Rusfertide for Polycythemia Vera
2
The OncFive: Top Oncology Articles for the Week of 8/23
3
DAWN-303 Trial Set to Advance INCB161734 in First-Line KRAS G12D–Mutated Metastatic Pancreatic Cancer
4
FDA Approves Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma
5